Back
GLP1RHGNC PubMed

Rare GLP1R variants attenuate weight loss with semaglutide but not tirzepatide

Levy ME, Schiabor Barrett KM, Telis N, et al. — Nat Metab 2026 · November 2026
Relevance score
6/10
Disease / domain
Variability in weight loss with GLP-1 receptor agonists
Source
PubMed
PMID 43015368

Gene–drug pair / mechanism

GLP1R

Rare damaging GLP1R variants attenuating the response to semaglutide, with no effect on the response to tirzepatide

Summary

Weight loss with GLP-1 receptor agonists is heterogeneous and its genetic determinants are not well known. The authors integrated exome sequencing with electronic health records in the Helix Research Network (n = 351,818). Among 13,725 adults treated with a GLP-1 receptor agonist, carriers of rare damaging GLP1R variants lose less weight with semaglutide than matched non-carriers but achieve a near-normal response with tirzepatide. Carriers of rare variants in GIPR, the second receptor targeted by tirzepatide, also achieve normal weight loss.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Analysis

A rare GLP1R variant that separates two related drugs is a direct lead for therapeutic choice, The abstract gives neither the number of carriers nor the weight-loss difference, and this is a health-record cohort: the clinical magnitude remains to be established and replication is needed before any pre-prescription test. No dosing or drug-choice recommendation follows at this stage.

Analysis by Dr Thibaut Benquey

Why this score?

Impact 2/3Evidence 2/3Novelty 1/2Sample 1/1Publication 0/1

Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 0/1 → Total: 6/10

Keywords

GLP1Rsemaglutidetirzepatideweight lossrare variants

More articles on GLP1R

Weekly report in your inbox

Every Wednesday · Annotated selection · Free · Unsubscribe anytime